PDGF与肿瘤信号转导通路

PDGF及其受体 PDGF由四种多肽链A、B、C、D以二
硫键形成二聚体结构，即可形成PDGF-A A、PDGF-BB、 PDGF-CC、PDGF-DD，此外，A链和B链还可形成异源的
二聚体，即PDGF-A B，因此目前发现的PDGF有五种二聚
体形式
[] 编码以上四条肽链的基因分别位于染色体7q22、
22q3、4q3和q22 [2] 。血小板源生长因子受体（PDGFR） 包括亚单位α 和β，每个亚单位由胞外配体结合区，跨胞 www.lungca.org b: one in eleven achieved PR, which last for sixteen point three months three in thirty achieved PR.
c: three in thirty achieved PR.
-: data was not available.
NSCLC: non-small cell lung cancer; mPFS: median progression-free survival; mOS: median overall survival.
RR means response rate which is express in percentage, and the unit of survival time (median progression-free survival and median overall survival) is week.
www.lungca.org 、林文俐 [6] 等的研究也支持了Cao的结 论。而Donnem等 [7] 则发现肿瘤细胞PDGF-AA的表达和淋
巴结转移相关，和预后关系不明确，PDGF-B（PDGF-BB或
PDGF-AB）和VEGFR-3的共表达和不良预后有关，和淋巴
手术标本进行免疫组化检测， 认为PDGFR与VEGFR-3可能 存在某种内在联系。吴丽娜等 [9] 则发现PDGF-B/PDGFR-α 自分泌刺激环可能在NSCLC的发生中起重要作用，且阳性 表达与疾病的分期呈正相关。
PDGF通路与肺癌治疗
靶向治疗 在对733例NSCLC肿瘤样本的染色体分
析中，R amos等 [20] 1/2+Sn CD/2/1 ---1/2: One week for chemotherapy treatment, followed by two weeks of no treatment.
2/1: Two consecutive weeks for once daily treatment, followed by two weeks of no treatment.
3/1: Three weeks for weekly paclitaxel therapy, followed by one week of no treatment.
CD: continuous daily dosing with no interval.
a: one in twenty-three achieved PR.
b: one in twenty-one achieved PR.
-: data were not available.
PD: Pulse dose bracketing each paclitaxel infusion.
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